Study analysis · Diabetes · 2024
This diabetes drug saves patients over $1,100 a year—without sending them to the hospital more often.
Empagliflozin costs less than GLP-1RA drugs for type 2 diabetes, with the same number of hospital visits.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at people who were already taking one of two diabetes medicines and saw that those on empagliflozin tended to spend less on pills and overall care. But it didn't randomly assign people — so we can't be sure the medicine itself caused the lower costs; maybe those people were healthier or had better insurance to begin with.
What’s the bottom line?
This study looked at two popular diabetes drugs to see which one costs less and causes similar hospital visits.
How strong is this study?
The researchers did a good job matching people who took each medicine so they were similar in age and health, which helps make the comparison fair. But because people chose their own medicine instead of being randomly assigned, there could still be hidden differences that affect the results — so we should be careful not to say one medicine definitely causes better outcomes.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
44 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=112942)+20/20
- Follow-upno follow-up reported
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 563 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study with propensity score matching, but without randomization or blinding. Confounding factors (e.g., patient health behaviors, physician prescribing patterns, comorbidities) cannot be fully ruled out, so cause-effect relationships cannot be established.
Major COI
Major conflicts that significantly reduce study credibility
The study was funded by Boehringer Ingelheim, and multiple authors have direct employment or financial ties to pharmaceutical companies whose drugs (empagliflozin and GLP-1RAs) are being compared, raising concerns about potential bias in study design and interpretation.
Funders
Conflict Details
None: None
None: None
Novo Nordisk: Other Relationship
Amarin Corporation: Research Support
Kowa Pharmaceuticals America, Inc.: Research Support
+11 more conflicts
The study compares empagliflozin (a Boehringer Ingelheim product) against GLP-1RAs, with multiple authors employed by competing pharmaceutical companies (Eli Lilly, Bayer) or receiving research funding from industry. The lead funder, Boehringer Ingelheim, employs one author and funds another, creating a significant conflict. No independent analysis safeguards are mentioned.
Key takeaways
- 01
Empagliflozin saved $1,116 per person per year in total costs and $800 in drug costs, with no difference in hospital or ER visits compared to GLP-1RA.
- 02
Yes — patients paid less for medications without more hospital trips, which matters for patients and insurers.
Surprising findings
- Empagliflozin saved $800 per year on pharmacy costs alone, while inpatient costs were nearly identical ($4 difference).Most assume expensive drugs like GLP-1RAs are more effective and justify their cost—but here, the cost gap is almost entirely from drug prices, not hospital use.
- The cost advantage persisted across both Medicare and commercial insurance populations.Drug pricing and formularies differ wildly between public and private payers—yet the savings were consistent, suggesting a systemic cost difference, not just plan-specific quirks.
Practical takeaways
If you have type 2 diabetes and are choosing between empagliflozin and a GLP-1RA, ask your doctor if cost is a factor—empagliflozin may save you $800+ a year on meds with no trade-off in hospital visits.
This study doesn’t compare weight loss, heart attack risk, or kidney protection—so if those are your priorities, GLP-1RAs may still be better.
medium confidenceInsurers and employers can use this data to prioritize empagliflozin in formularies to reduce overall diabetes care costs without increasing utilization.
Real-world prescribing is influenced by marketing, patient preference, and physician habit—not just cost data.
medium confidenceWhy this study matters
The $1,116 Savings Secret
The study found that patients taking empagliflozin had $1,116 lower total healthcare costs and $800 lower pharmacy costs per year compared to those on GLP-1 receptor agonists—despite no difference in hospital or ER visits.
For patients on fixed incomes or insurers paying the bill, this isn’t just a number—it’s real money saved on meds and care, making diabetes management more affordable.
Same Hospital Visits, Lower Costs
Despite lower drug costs, empagliflozin users had nearly identical rates of hospitalizations (RR 0.99) and ER visits (RR 0.98) as GLP-1RA users, meaning cost savings weren’t due to reduced care.
People assume cheaper drugs mean worse care—but this shows you can cut costs without sacrificing health outcomes.
Works for Medicare AND Private Insurance
The cost advantage of empagliflozin held true across both Medicare fee-for-service and commercial insurance populations, suggesting broad real-world applicability.
Most drug studies focus on one group—but this shows the savings work for seniors on Medicare and working adults with private plans.
Heart Patients Benefit Too
Even in patients with existing cardiovascular disease—often considered high-risk—the same $1,116 cost savings and no increase in hospital visits were observed.
Doctors often assume high-risk patients need pricier drugs—but this suggests empagliflozin is just as effective and cheaper, even for the sickest.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at two popular diabetes drugs to see which one costs less and causes similar hospital visits.
Research results
Empagliflozin saved $1,116 per person per year in total costs and $800 in drug costs, with no difference in hospital or ER visits compared to GLP-1RA.
What this means - more context
Yes — patients paid less for medications without more hospital trips, which matters for patients and insurers.
This study compares healthcare utilization and costs between empagliflozin and GLP-1 receptor agonists in U.S. adults with type 2 diabetes.
In over 112,000 propensity score-matched patients, empagliflozin was associated with similar hospitalizations and emergency room visits but lower total and pharmacy costs compared to GLP-1RA, with consistent results in patients with cardiovascular disease and across Medicare and commercial insurance populations.
Methods Used
Retrospective observational cohort study using U.S. Medicare fee-for-service and Optum commercial claims (2014–2019); 1:1 propensity score matching of adults with type 2 diabetes initiating empagliflozin or GLP-1RA; estimated rate ratios and cost differences per member per year.
Main Finding
Empagliflozin initiation was associated with $1,116 lower total and $800 lower pharmacy costs per member per year compared to GLP-1RA, with no significant difference in hospitalizations or emergency room visits.
Confidence Level
Moderate; strong sample size and propensity score matching reduce confounding, but observational design limits causal inference.
Study Flags
Red Flags
- •Observational design — cannot prove causation
- •Funding from drug manufacturers (Boehringer-Ingelheim, Eli Lilly)
- •Potential unmeasured confounders in claims data
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Empagliflozin saved $800 per year on pharmacy costs alone, while inpatient costs were nearly identical ($4 difference).
Most assume expensive drugs like GLP-1RAs are more effective and justify their cost—but here, the cost gap is almost entirely from drug prices, not hospital use.
Practical Takeaways
If you have type 2 diabetes and are choosing between empagliflozin and a GLP-1RA, ask your doctor if cost is a factor—empagliflozin may save you $800+ a year on meds with no trade-off in hospital visits.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 563 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study looked at people who were already taking one of two diabetes medicines and saw that those on empagliflozin tended to spend less on pills and overall care. But it didn't randomly assign people — so we can't be sure the medicine itself caused the lower costs; maybe those people were healthier or had better insurance to begin with.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Large sample size (n=112,942)
- Use of propensity score matching to balance baseline characteristics
- Use of real-world claims data from two large U.S. databases (Medicare and Optum)
Weaknesses
- Non-randomized design introduces potential for unmeasured confounding
- Blinding status unknown, so outcome ascertainment may be biased
- Reliance on claims data may misclassify diagnoses or treatments
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at two popular diabetes drugs to see which one costs less and causes similar hospital visits.
Research results
Empagliflozin saved $1,116 per person per year in total costs and $800 in drug costs, with no difference in hospital or ER visits compared to GLP-1RA.
What this means - more context
Yes — patients paid less for medications without more hospital trips, which matters for patients and insurers.
This study compares healthcare utilization and costs between empagliflozin and GLP-1 receptor agonists in U.S. adults with type 2 diabetes.
In over 112,000 propensity score-matched patients, empagliflozin was associated with similar hospitalizations and emergency room visits but lower total and pharmacy costs compared to GLP-1RA, with consistent results in patients with cardiovascular disease and across Medicare and commercial insurance populations.
Methods Used
Retrospective observational cohort study using U.S. Medicare fee-for-service and Optum commercial claims (2014–2019); 1:1 propensity score matching of adults with type 2 diabetes initiating empagliflozin or GLP-1RA; estimated rate ratios and cost differences per member per year.
Main Finding
Empagliflozin initiation was associated with $1,116 lower total and $800 lower pharmacy costs per member per year compared to GLP-1RA, with no significant difference in hospitalizations or emergency room visits.
Confidence Level
Moderate; strong sample size and propensity score matching reduce confounding, but observational design limits causal inference.
Study Flags
Red Flags
- •Observational design — cannot prove causation
- •Funding from drug manufacturers (Boehringer-Ingelheim, Eli Lilly)
- •Potential unmeasured confounders in claims data
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Empagliflozin saved $800 per year on pharmacy costs alone, while inpatient costs were nearly identical ($4 difference).
Most assume expensive drugs like GLP-1RAs are more effective and justify their cost—but here, the cost gap is almost entirely from drug prices, not hospital use.
Practical Takeaways
If you have type 2 diabetes and are choosing between empagliflozin and a GLP-1RA, ask your doctor if cost is a factor—empagliflozin may save you $800+ a year on meds with no trade-off in hospital visits.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 563 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study looked at people who were already taking one of two diabetes medicines and saw that those on empagliflozin tended to spend less on pills and overall care. But it didn't randomly assign people — so we can't be sure the medicine itself caused the lower costs; maybe those people were healthier or had better insurance to begin with.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Large sample size (n=112,942)
- Use of propensity score matching to balance baseline characteristics
- Use of real-world claims data from two large U.S. databases (Medicare and Optum)
Weaknesses
- Non-randomized design introduces potential for unmeasured confounding
- Blinding status unknown, so outcome ascertainment may be biased
- Reliance on claims data may misclassify diagnoses or treatments
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The researchers did a good job matching people who took each medicine so they were similar in age and health, which helps make the comparison fair. But because people chose their own medicine instead of being randomly assigned, there could still be hidden differences that affect the results — so we should be careful not to say one medicine definitely causes better outcomes.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
44 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=112942)+20/20
- Follow-upno follow-up reported
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 563 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study with propensity score matching, but without randomization or blinding. Confounding factors (e.g., patient health behaviors, physician prescribing patterns, comorbidities) cannot be fully ruled out, so cause-effect relationships cannot be established.
Major COI
Major conflicts that significantly reduce study credibility
The study was funded by Boehringer Ingelheim, and multiple authors have direct employment or financial ties to pharmaceutical companies whose drugs (empagliflozin and GLP-1RAs) are being compared, raising concerns about potential bias in study design and interpretation.
Funders
Conflict Details
None: None
None: None
Novo Nordisk: Other Relationship
Amarin Corporation: Research Support
Kowa Pharmaceuticals America, Inc.: Research Support
+11 more conflicts
The study compares empagliflozin (a Boehringer Ingelheim product) against GLP-1RAs, with multiple authors employed by competing pharmaceutical companies (Eli Lilly, Bayer) or receiving research funding from industry. The lead funder, Boehringer Ingelheim, employs one author and funds another, creating a significant conflict. No independent analysis safeguards are mentioned.